Integrin α vβ 3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model

Molecular Imaging

Volumn 11, Issue 4, 2012, Pages 286-300

  Chen, Wei Tsung ^a,b,c,d,e   Fang Shih, Tiffany Ting ^a,b,c,d,e   Chen, Ran Chou ^a,b,c,d,e   Tu, Shin Yang ^a,b,c,d,e   Wen Yuen, Hsieh ^a,b,c,d,e   Yang, Pang Chyr ^a,b,c,d,e  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-ANGIOGENIC THERAPY; ANTIANGIOGENIC; BEVACIZUMAB; CELLULAR ATTACHMENTS; CONTROL GROUPS; DCE-MRI; DYNAMIC CONTRAST; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; GD-DTPA; IN-VITRO; INTEGRINS; MAGNETIC RESONANCE CONTRAST AGENTS; TREATMENT GROUP; TREATMENT RESPONSE; TUMOR ANGIOGENESIS; TUMOR MODELS; TUMOR SIZE;

BIOLOGICAL MATERIALS; DENDRIMERS; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MAMMALS; MONOCLONAL ANTIBODIES;

TUMORS;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CONTRAST MEDIUM; DENDRIMER; GADOLINIUM PENTETATE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; VITRONECTIN RECEPTOR;

ANIMAL; CELL ADHESION; DIAGNOSTIC USE; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PATHOLOGY; SCINTISCANNING; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ADHESION; CELL LINE, TUMOR; CONTRAST MEDIA; DENDRIMERS; GADOLINIUM DTPA; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MALE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866884311     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00050     Document Type: Article

References (50)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6, doi:10.1093/jnci/82.1.4.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31, doi:10.1038/nm0195-27.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50, doi:10.1056/NEJMoa061884.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42, doi:10.1056/NEJM oa032691.
5. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76, doi:10.1056/NEJMoa072113.
6. Varner JA. The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS 1997;79:361-90.
7. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996; 32A:2423-9, doi:10.1016/S0959-8049(96)00381-4.
8. Brooks PC, Clark RA. Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71, doi:10.1126/science.7512751.
9. De S, Razorenova O, McCabe NP, et al. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 2005;102:7589-94, doi:10.1073/pnas.0502935102.
10. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64, doi:10.1016/0092-8674(94)90007-8.
11. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004;53:1831-40, doi:10.2337/diabetes.53.7.1831.
12. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991;16:246-50, doi:10.1016/0968- 0004(91)90096-E.
13. Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibiotrs of the avb3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997;36:1374-89, doi:10.1002/anie. 199713741.
14. Aumailley M, Gurrath M, Muller G, et al. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991; 291:50-4, doi:10.1016/0014-5793(91)81101-D.
15. Gurrath M, Muller G, Kessler H, et al. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992;210:911-21, doi:10.1111/j.1432-1033.1992.tb17495.x.
16. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
17. Cai W, Sam Gambhir S, Chen X. Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques 2005;39(6 Suppl): S14-25, doi:10.2144/000112091.
18. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439-55, doi:10.2174/1381612043384745.
19. Cai W, Chen K, Li ZB, et al. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007;48:1862-70, doi:10.2967/jnumed.107.043216.
20. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004;64:8009-14, doi:10.1158/0008-5472.CAN-04-1956.
21. Cheng Z, Wu Y, Xiong Z, et al. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 2005;16:1433-41, doi:10.1021/bc0501698.
22. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med 2005;2: e70, doi:10.1371/journal.pmed. 0020070.
23. Li C, Wang W, Wu Q, et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol 2006;33:349-58, doi:10.1016/j.nucmedbio.2006.01.001.
24. Li ZB, Cai W, Cao Q, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48:1162-71, doi:10.2967/jnumed.107.039859.
25. Sancey L, Ardisson V, Riou LM, et al. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 2007;34: 2037-47, doi:10.1007/s00259-007-0497-z.
26. Hollingworth W, Todd CJ, Bell MI, et al. The diagnostic and therapeutic impact of MRI: an observational multi-centre study. Clin Radiol 2000;55:825-31, doi:10.1053/crad.2000.0546.
27. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63:5838-43.
28. Schmieder AH, Winter PM, Caruthers SD, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005;53:621-7, doi:10.1002/mrm.20391.
29. Mulder WJ, Strijkers GJ, Habets JW, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 2005; 19:2008-10.
30. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008;49:1371-9, doi:10.2967/jnumed.108.051243.
31. Huo T, Du X, Zhang S, et al. Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin alphanubeta3 receptor-expressed tumor-MR molecular imaging of angiogenesis. Eur J Radiol 2010; 73:420-7, doi:10.1016/j.ejrad.2008.11.025.
32. Boles KS, Schmieder AH, Koch AW, et al. MR angiogenesis imaging with Robo4-vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010;24:4262-70, doi:10.1096/fj.10-157933.
33. Schmieder AH, Caruthers SD, Zhang H, et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J 2008;22:4179-89, doi:10.1096/fj.08-112060.
34. Chen WT, Thirumalai D, Shih T, et al. Dynamic contrastenhanced folate-receptor-targeted MR imaging using a Gd-loaded PEG-dendrimer-folate conjugate in a mouse xenograft tumor model. Mol Imaging Biol 2010;12:145-54, doi:10.1007/s11307-009-0248-6.
35. Kim TI, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009; 50:4653-9, doi:10.1167/iovs.08-2805.
36. Xiao W, Yao N, Peng L, et al. Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. Eur J Nucl Med Mol Imaging 2009;36:94-103, doi:10.1007/s00259-008-0920-0.
37. Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11: 6270-9, doi:10.1158/1078-0432.CCR-04- 1223.
38. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54, doi:10.1007/BF00300234.
39. El Khouli RH, Macura KJ, Jacobs MA, et al. Dynamic contrastenhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol 2009;193:W295-300, doi:10.2214/AJR.09.2483.
40. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4: 123-31, doi:10.2174/1389450033346830.
41. Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. J Biol Chem 2004;279:4862-8, doi:10.1074/jbc.M305190200.
42. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000;156:1673-83, doi:10.1016/S0002-9440(10)65038-9.
43. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9; discussion 90.
44. Wu X, Jeong EK, Emerson L, et al. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm 2010;7:41-8, doi:10.1021/mp900153f.
45. Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009;29:1125-33, doi:10.1002/jmri.21710.
46. Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004;20:865-73, doi:10.1002/jmri.20184.
47. Piessevaux H, Buyse M, De Roock W, et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009;20:1375-82, doi:10.1093/annonc/mdp011.
48. Zhou XL, Luo Z, Tang DZ, et al. Preparation of targeted Gd3+ contrast agent based on folate-receptor and its relaxation. Zhongguo Yaoxue Zazhi 2007;42:1640-4.
49. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-610, doi:10.1038/sj.bjc.6602550.
50. Ho S, Lau WY, Leung WT, et al. Arteriovenous shunts in patients with hepatic tumors. J Nucl Med 1997;38:1201-5.